![[Most Recent Quotes from www.kitco.com]](http://www.kitconet.com/charts/metals/gold/t24_au_en_usoz_2.gif)
![[Most Recent Quotes from www.kitco.com]](http://www.kitconet.com/charts/metals/silver/t24_ag_en_usoz_2.gif)
FDA Table of Potential Drug Risks – from Adverse Event Reporting System (AERS)
Mike Havrilla (September 6th, 2008) Writes:
The FDA has published a table with the names of products and potential signals of serious risks and/or new safety information identified for these products during 1Q08 in the AERS database. The FDA notes that patients should not stop taking these medications and should consult their prescriber with any questions as the agency will investigate each of the claims further before taking action or issuing more definitive statements on the reported concerns. Some highlights from this table of products that are sold by public-traded pharma and biotech companies are listed below in the following format: active ingredient (brand name) - company(ies) - new safety information reported.
Duloxetine (Cymbalta) - Eli Lilly (LLY) - Urinary retention
Heparin - Baxter (BAX) & APP Pharma (APPX) - Anaphylactic-type reactions
Lapatinib (Tykerb) - GlaxoSmithKline (GSK) – Liver toxicity
Lenalidomide (Revlimid) - Celgene (CELG) – ...
Tags for this Post:
Astrazeneca, Baxter, Biogen, brain disorder, cancer, Celgene, Duloxetine, eln, Fda, Glaxosmithkline, ileus, Lapatinib, Lenalidomide, Market Commentary, Mississippi, multiple myeloma, Multiple Sclerosis, Natalizumab, New England Journal, Novartis, Octreotide Acetate Depot, Quetiapine, Sandostatin LAR, skin cancer, skin disease, Telbivudine, the New England Journal of Medicine, treatment of the blood-based cancer, Tysabri
Astrazeneca, Baxter, Biogen, brain disorder, cancer, Celgene, Duloxetine, eln, Fda, Glaxosmithkline, ileus, Lapatinib, Lenalidomide, Market Commentary, Mississippi, multiple myeloma, Multiple Sclerosis, Natalizumab, New England Journal, Novartis, Octreotide Acetate Depot, Quetiapine, Sandostatin LAR, skin cancer, skin disease, Telbivudine, the New England Journal of Medicine, treatment of the blood-based cancer, Tysabri
No recommendations, either expressed or implied, are being made to buy, sell, hold or short any of the mentioned stocks. No legal, tax or accounting advice is expressed or implied. Always contact your attorney, CPA, or tax advisor before acting on any legal or tax issues. StraightStocks.com is not responsible for the content, products, or services of any of the advertisers on this site. StraightStocks.com receives compensation from advertisers on this blog. Services and products referred to herein are trademarks, registered trademarks, servicemarks, and/or registered servicemarks of their respective trademark or servicemark owners.